Clinical Trials Logo

Filter by:
NCT ID: NCT05431348 Not yet recruiting - Glioblastoma (GBM) Clinical Trials

Effect of stRess and exeRcize on the Outcome After Chemo-Radiation

ERROR
Start date: June 2022
Phase:
Study type: Observational

Glioblastoma (GBM) is a highly malignant, incurable primary brain tumor. Due to the nature of this disease and the extent of the treatment (surgery followed by chemoradiation according to the Stupp trial) patients undergo considerable psychological distress. It is known that stress hormones are involved in a wide range of processes involved in cell survival, cell cycle and immune function, and can cause therapy resistance. In this study the effect of stress on outcome after chemoradiation in patients with GBM will be investigated.

NCT ID: NCT05431140 Recruiting - Type 1 Diabetes Clinical Trials

Evaluation of CloudCare in the Treatment of Type 1 Diabetes

Start date: June 20, 2022
Phase:
Study type: Observational

CloudCare is an eHealth application to help health care professionals (HCP) in the management/treatment of type 1 diabetes. The application will automatically check all uploaded glucose parameters from patients glucose monitoring devices and present all these data in a categorized way (using a so called dashboard) to the HCP. In this way the HCP has a direct overview of the condition of her/his patients, and can determine which data request direct action towards the patient and which data do not. It is expected that this system improves outcome and patient experience. In this study this expectation will be studied by measuring the effect of CloudCare on patients' treatment satisfaction, glucose control, HCP satisfaction and the impact on costs.

NCT ID: NCT05431101 Recruiting - Clinical trials for Carpal Tunnel Syndrome

abSorbable vErsus Non-absorbable SuturEs for Wound Closure in Carpal Tunnel Release

SENSE
Start date: May 1, 2022
Phase: N/A
Study type: Interventional

Carpal Tunnel Syndrome is a prevalent condition, up to 9% in women and 0.6% in men. Surgical decompression in the most effective treatment. After surgery, approximately 1,8% of the patients develop a wound infection. Possibly, the type of sutures used can influence the prevalence of wound infection. In this RCT the incidence of infection is investigated between the use of absorbable versus non-absorbable sutures in carpal tunnel release.

NCT ID: NCT05430516 Completed - SARS-CoV-2 Clinical Trials

Within Household Transmission of COVID-19 Infections

VERDI
Start date: January 15, 2022
Phase:
Study type: Observational

In the absence of a vaccine, the spread of SARS-CoV-2 can only be mitigated via non-pharmaceutical interventions that reduce the risks of forward transmission. Currently, European policymakers are implementing combinations of fierce pandemic control measures. However, there is substantial uncertainty on the transmission dynamics of SARS-CoV-2 and, consequently, the effect of each specific mitigation intervention as well as their joint impact on the pandemic evolution. Moreover, it is uncertain how and when the Public Health response should be modified once the pandemic starts to slow. There is an urgent need for data that can help to further unravel the key transmission characteristics of SARS-CoV-2 in the population. Household studies are, therefore, a useful approach to obtain insight into the main determinants of transmission and to derive estimates of transmission parameters. By fully characterizing the critical process of SARS-CoV-2 household transmission and how they vary by patient and household characteristics, infection dynamics in the population can be further elucidated. Responding to SARS-CoV-2 effectively from a community care perspective will also require understanding the perceptions, beliefs, and actions taken by patients and the public. A 'bottom-up' understating of such issues is critical to understand how best to design effective community strategies. Rapid European COVID-19 Emergency Research response (RECOVER) is a project involving ten international partners that have been selected for funding by the European Union under the Horizon 2020 research framework. RECOVER responds to call topic SC1-PHE-CORONAVIRUS-2020: Advancing knowledge for the clinical and public health response to the SARS-CoV-2 epidemic and builds on many years of investment by the European Commission in clinical research preparedness for epidemic response. RECOVER will therefore provide a range of data and analytical results to guide the Public Health response, including the here described household transmission study. Objective: Estimate key transmission parameters of SARS-CoV-2 in Europe from observing within household virus spread and seroconversion of household members and characterize the views and experiences of households regarding perceptions, practices regarding infection control, and impacts of imposed isolation measures.

NCT ID: NCT05429840 Recruiting - Clinical trials for Neuroinflammatory Response

Safety & PK of Single Doses of MT1980

Start date: June 1, 2022
Phase: Phase 1
Study type: Interventional

MT1980 is being developed as a treatment for neuroinflammation (an inflammatory response in the brain and/or spinal cord). Much research has focused on the central role of neuroinflammation in the pathogenesis of many conditions relating to the CNS, including eg, traumatic brain injury, stroke, Alzheimer's disease, post-operative cognitive decline (POCD)/perioperative neurocognitive disorder, and now even long-term cognitive side effects from severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). Current anti-inflammatories do not easily cross the blood-brain barrier from the systemic circulation to the brain, making neuroinflammation a difficult condition to treat. This will be a Phase 1, single dose, randomized, placebo-controlled study in healthy subjects. The study will provide information on the safety of MT1980, the systemic bioavailability of the active drug, and levels of the active drug in the CSF. The study will be conducted in two parts. In Part 1, subjects will be randomized to receive a single oral dose of MT1980 or placebo in a parallel design. An interim PK and safety data analysis will be performed after Part 1 prior to dose selection in Part 2. In Part 2 subjects will be randomized to receive either placebo or a single oral dose of MT1980 at one of 2 strengths in a parallel design.

NCT ID: NCT05429190 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Validation of SMS Protocol for HCC Screening in High-risk Patients

Start date: August 1, 2022
Phase:
Study type: Observational

The investigators will assess implementation of the proposed SMS protocol as a surveillance tool in patients at high risk of developing HCC in a prospective multicenter study.

NCT ID: NCT05427773 Not yet recruiting - Clinical trials for Pulmonary Disease, Chronic Obstructive

(In)Voluntary Assessed Quadriceps Muscle Endurance in COPD

Bionic
Start date: June 2022
Phase:
Study type: Observational

The primary objective is to assess the relation between involuntary and voluntary assessed quadriceps muscle endurance in patients with COPD. We hypothesized a good correlation (>0.8) between the measurements.

NCT ID: NCT05426538 Recruiting - Asthma Clinical Trials

Craving to Biologics Used in Severe Asthma

CROCUS
Start date: December 10, 2021
Phase:
Study type: Observational

Some patients treated with biologics for severe asthma experience a craving to the next biological administration. This phenomenon has never been described before. In this study, the researchers aim to further elucidate the feeling of needing the next administration of a biologic for severe asthma.

NCT ID: NCT05426122 Recruiting - Digestive System Clinical Trials

Degree of Digestibility of Barley Rice Proteins

Bar-pro
Start date: June 29, 2022
Phase: N/A
Study type: Interventional

This study aims to assess the degree of digestibility of barley rice protein and compare this to another sustainable, commercially available protein concentrate (pea protein), and a benchmark whey protein, and to assess the effects on blood glucose and insulin levels. The study is a randomized, cross-over, double blind, controlled trial. Three different treatments, all representing a 20g protein load, will be evaluated with a washout period of minimum one week between the test days. Blood will be collected via a catheter before and up-to five hours after protein consumption. Wellbeing, health complaints or other adverse effects will be collected via a short questionnaire during each test day. After each test day gastrointestinal complaints are collected via an online questionnaire.

NCT ID: NCT05423886 Not yet recruiting - Colorectal Cancer Clinical Trials

The Effectiveness of Personalized Colorectal Cancer Screening Based on Fecal Hemoglobin Concentration

PERFECT-FIT
Start date: September 2022
Phase: N/A
Study type: Interventional

We aim to improve the yield and effectiveness of the Dutch colorectal cancer screening program by using a personalized screening strategy based on fecal Hemoglobin concentration in previous screening round for participants with a negative fecal immunochemical test (FIT).